Compare · BSX vs NSPR
BSX vs NSPR
Side-by-side comparison of Boston Scientific Corporation (BSX) and InspireMD Inc. (NSPR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BSX and NSPR operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX is the larger of the two at $62.37B, about 2051.0x NSPR ($30.4M).
- NSPR has been more active in the news (19 items in the past 4 weeks vs 13 for BSX).
- BSX has more recent analyst coverage (25 ratings vs 1 for NSPR).
- Company
- Boston Scientific Corporation
- InspireMD Inc.
- Price
- -
- -
- Market cap
- $62.37B
- $30.4M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 13
- 19
- Recent ratings
- 25
- 1
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
InspireMD Inc.
InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions. It is also developing NGuard, a neurovascular flow diverter that diverts blood flow away from cerebral aneurysms and seals the aneurysms. The company sells its products through local distributors. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv, Israel.
Latest BSX
- Boston Scientific Corporation filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits
- Chairman, President & CEO Mahoney Michael F received a gift of 252,241 shares (SEC Form 4)
- SVP, Chief HR Officer O'Sullivan Miriam converted options into 3,871 shares and covered exercise/tax liability with 1,872 shares, increasing direct ownership by 11% to 19,565 units (SEC Form 4)
- Blackstone Life Sciences Announces $455 Million Collaboration to Co-Fund Development of Boston Scientific VITALYST™ Heart Pump for Patients with Cardiogenic Shock
- SEC Form 10-Q filed by Boston Scientific Corporation
- SIMPLAAFY study of the WATCHMAN FLX™ Pro Left Atrial Appendage Closure Device meets primary endpoints
- Boston Scientific downgraded by TD Cowen with a new price target
- Penumbra, Inc. Reports Third Quarter 2026 Financial Results
- Boston Scientific downgraded by Oppenheimer
- Boston Scientific downgraded by Analyst with a new price target
Latest NSPR
- InspireMD to Host KOL Webinar on Carotid Artery Disease Management and the Clinical Benefits of InspireMD’s CGuard Prime Carotid Stent Platform
- Chief Financial Officer Michael A Lawless bought $75,000 worth of shares (115,385 units at $0.65), increasing direct ownership by 17% to 807,080 units (SEC Form 4)
- CEO and President Marvin Slosman bought $30,000 worth of shares (46,154 units at $0.65), increasing direct ownership by 1% to 3,602,812 units (SEC Form 4)
- Director Michael Berman bought $50,000 worth of shares (76,923 units at $0.65), increasing direct ownership by 22% to 429,509 units (SEC Form 4)
- Director Gary S Roubin bought $100,000 worth of shares (153,846 units at $0.65), increasing direct ownership by 18% to 988,324 units (SEC Form 4)
- Director Paul Stuka bought $200,000 worth of shares (307,693 units at $0.65) (SEC Form 4)
- SEC Form 10-Q filed by InspireMD Inc.
- InspireMD Announces Talks Featuring CGuard and CGuard Prime at VEITHsymposium 2026
- InspireMD Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
- SEC Form 424B5 filed by InspireMD Inc.